Sun Pharmaceutical Industries Schedules Board Meeting for Q3FY26 Results and Interim Dividend Consideration

Sun Pharmaceutical Industries Limited has announced a board meeting scheduled for January 31, 2026, to review quarterly financial performance and consider dividend distribution to shareholders. The pharmaceutical major will deliberate on key financial matters including unaudited results and potential interim dividend declaration.

Board Meeting Agenda

The board meeting will address two primary agenda items for the company's financial review:

Agenda Item:	Details
Financial Results:	Unaudited Standalone and Consolidated Financial Results for quarter and nine months ended December 31, 2025
Dividend Consideration:	Declaration of Interim Dividend for financial year 2025-26

Interim Dividend Details

The company has established specific parameters for the potential interim dividend distribution. Key details regarding the dividend process include:

Parameter:	Information
Record Date:	February 5, 2026
Eligibility:	Equity shareholders on Register of Members as of record date
Tax Deduction:	Tax at source deduction at prescribed rates
Documentation:	Comprehensive guidance available on company website

Shareholders are advised to update their information with the depository for dematerialized shares and with MUFG Intime India Pvt. Ltd (formerly Link Intime India Pvt. Ltd.), the company's Registrar and Share Transfer Agent, for physical shares to ensure timely dividend receipt.

Trading Window Restrictions

In compliance with regulatory requirements, the company has implemented trading window restrictions during the financial results period:

Closure Date: January 1, 2026
Reopening Date: February 2, 2026
Duration: 32 days total closure period

The trading window closure aligns with SEBI regulations regarding insider trading restrictions during periods of material information disclosure.

Regulatory Compliance

The board meeting announcement has been made under Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company has notified both the National Stock Exchange of India Limited (NSE Code: SUNPHARMA) and BSE Limited (Stock Code: 524715) regarding the scheduled meeting and related matters.

The pharmaceutical company continues to maintain transparency in its corporate governance practices through timely disclosure of material information to stakeholders and regulatory authorities.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
-3.68%	-7.04%	-7.51%	-4.71%	-9.25%	+170.52%

Sun pharmaceutical Industries Ltd. executed a significant block trade on the National Stock Exchange (NSE), marking a notable institutional transaction in the pharmaceutical sector.

Transaction Details

The block trade involved substantial volume and value, demonstrating institutional interest in the pharmaceutical major's shares.

Parameter:	Details
Total Transaction Value:	₹20.56 crores
Number of Shares:	~125,250 shares
Execution Price:	₹1,641.20 per share
Exchange:	National Stock Exchange (NSE)

Block Trade Mechanism

Block trades represent large-volume transactions executed outside regular market hours or through special trading windows. These transactions allow institutional investors to trade substantial quantities without significantly impacting the stock's market price. The mechanism provides efficient execution for large orders while maintaining market stability.

Market Implications

The execution of this block trade indicates institutional activity in Sun Pharmaceutical Industries' shares. Such transactions typically involve institutional investors, mutual funds, or other large market participants seeking to adjust their portfolio positions. The specific price of ₹1,641.20 per share reflects the negotiated rate between the participating parties in this off-market transaction.